Boehringer Ingelheim International Gmbh

Thomas Klein

Michael Mark

Rolf Grempler

Waldemar F Pfrengle

Hans-Juergen Woerle

Markus Frank

Andreas Daiber

Maximilian Von Eynatten

Sanjaykumar Patel

Leo Thomas

Klaus Dugi

Uli Christian Broedl

Odd-Erik Johansen

Eva Ulrike Graefe-Mody

Berthold Hocher

Thomas Muenzel

Eric Williams Mayoux

Richard Ernest Gilbert

Yuliya Sharkovska

Odd-Eric Johansen

Kim Alexander Connelly

Andrew Advani

Gerd Luippold

Heiko Niessen

The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.

Use of a DPP-4 inhibitor in SIRS and/or sepsis

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.

Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Vasoprotective and cardioprotective antidiabetic therapy

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.

Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.

Combination therapy

The present invention relates to the use of a certain DPP-4 inhibitor for modifying food intake and regulating food preference.

Method for modifying food intake and regulating food preference with a DPP-4 inhibitor

The present invention relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for use in a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF).

Medical use of a DPP-4 inhibitor

The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions

The invention relates to the treatment of metabolic disorders in an overweight or obese patient characterized in that empagliflozin and one or more antiobesity drugs are administered to the patient.

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.

Diabetes therapy

The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV(DPP-IV).

Growing community of inventors

Radolfzell, Germany

Thomas Klein